Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
McMaster University
$27,000.00
Investigating germline immunoediting in glioma
EF 2025-26
Résumé
No two cancers are the same. The genetic mutations that make each tumour unique also make treatment difficult—what works for one patient often fails for another. My research seeks to uncover why tumours develop different mutations in the first place. Recent evidence suggests that the DNA we inherit from our parents may influence not only cancer risk, but also the specific mutations a tumour develops. Gliomas, the most common malignant brain tumour in adults, offer a powerful model to explore this phenomenon. Gliomas are classified based on the mutations they develop that determine both diagnosis and outcome. Survival ranges from about 70% for low-grade gliomas to less than 5% for the most aggressive forms. Understanding why some individuals develop mutations linked to poorer prognosis could transform early detection and treatment. Using large-scale genomics data, this project will test whether inherited DNA variants influence immune response to specific cancer-causing mutations in glioma through a process we call germline-mediated immunoediting. This research has two key objectives: first, to identify cancer-causing mutations that show evidence of germline-mediated immunoediting by quantifying the absence of these mutations in individuals predicted to have more anti-tumour immune responses based on their inherited DNA. Second, to evaluate whether these inherited DNA variants associated with differential immune response are also associated with patient survival using multivariate regression models. By linking inherited immunity to mutation burden and outcomes seen in glioma, this research could help us understand the evolution of tumours and develop blood-based biomarkers for early detection and prognosis.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
573269
Name
Apel Erika
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating germline immunoediting in glioma
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Bioinformatics; Genomics; Germline Variants; Glioma; Immunoediting; Tumour Immunology
Abstract
No two cancers are the same. The genetic mutations that make each tumour unique also make treatment difficult—what works for one patient often fails for another. My research seeks to uncover why tumours develop different mutations in the first place. Recent evidence suggests that the DNA we inherit from our parents may influence not only cancer risk, but also the specific mutations a tumour develops. Gliomas, the most common malignant brain tumour in adults, offer a powerful model to explore this phenomenon. Gliomas are classified based on the mutations they develop that determine both diagnosis and outcome. Survival ranges from about 70% for low-grade gliomas to less than 5% for the most aggressive forms. Understanding why some individuals develop mutations linked to poorer prognosis could transform early detection and treatment. Using large-scale genomics data, this project will test whether inherited DNA variants influence immune response to specific cancer-causing mutations in glioma through a process we call germline-mediated immunoediting. This research has two key objectives: first, to identify cancer-causing mutations that show evidence of germline-mediated immunoediting by quantifying the absence of these mutations in individuals predicted to have more anti-tumour immune responses based on their inherited DNA. Second, to evaluate whether these inherited DNA variants associated with differential immune response are also associated with patient survival using multivariate regression models. By linking inherited immunity to mutation burden and outcomes seen in glioma, this research could help us understand the evolution of tumours and develop blood-based biomarkers for early detection and prognosis.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Apel, Erika
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~